Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp executive Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share, then sold 8,300 shares in several trades on August 6, 2026, at weighted‑average prices per share including $512.9174 and $521.4972. After the exercise he held 72,440 stock options. The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered into on August 11, 2025.
United Therapeutics Chairperson & CEO Martine A. Rothblatt, via a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 shares in multiple trades on August 5, 2026. These transactions were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, which contemplates exercising up to 1,734,410 options expiring March 15, 2027. Following this exercise, a family trust continues to hold 198,910 stock options, and Rothblatt also reports 40,513 common shares held directly, in addition to other indirect holdings through family trusts.
Holder Paul Mahon filed to sell up to 8,300 shares of UTHR common stock through Morgan Stanley Smith Barney’s Executive Financial Services, with an indicated aggregate market value of $4,291,512.51, and with 42,890,692 shares of the class reported as outstanding on NASDAQ as of 08/06/2026. The filing also lists a pattern of prior open-market sales over the past three months, each for 8,300 shares, including transactions on 07/16/2026 for $4,429,637.79, 07/02/2026 for $4,586,274.56, and earlier dates in May and June 2026 with similar block sizes and multi-million-dollar dollar amounts.
United Therapeutics chairperson and CEO Martine A. Rothblatt, indirectly through family trusts, exercised 9,500 stock options at $135.4200 per share on August 4, 2026 and received an equal number of common shares.
On the same date those 9,500 shares were sold in multiple tranches at reported weighted average prices such as $512.4859, $516.5935 and $517.4960 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
The plan continues until the earlier of exercising up to 1,734,410 stock options expiring March 15, 2027 or December 31, 2026; 208,410 stock options remain held indirectly in a family trust, plus 40,513 shares held directly and 166 shares held indirectly by a spouse.
United Therapeutics Corporation reported second quarter 2026 results with total revenues of $783.3 million, a 2 percent decrease from $798.6 million a year earlier, as lower Nebulized Tyvaso and Remodulin sales offset growth in Tyvaso DPI, Orenitram, and Unituxin. U.S. revenues were $733.6 million and rest-of-world revenues were $49.7 million.
Net income rose to $333.0 million from $309.5 million, with diluted EPS increasing to $7.27 from $6.41. Cost of sales increased 14 percent to $99.5 million, driven partly by higher inventory reserves including $7.5 million of estimated losses under a Tyvaso DPI supply agreement. Research and development expense grew 9 percent to $146.3 million, reflecting higher cardiopulmonary project spending and higher contingent consideration, while selling, general, and administrative expense declined 3 percent to $206.7 million due to the non-recurrence of a 2025 PP&E impairment. The effective tax rate fell to 11 percent from 24 percent, mainly from higher excess tax benefits on share-based compensation.
The company highlighted record Tyvaso DPI patient metrics and stated that it has submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF, with plans to submit an IND for ralinepag DPI and an NDA for treprostinil SMI later in 2026. Management described these programs as potential multi-billion-dollar growth catalysts and noted continued advancement of an organ manufacturing pipeline and plans to launch two xeno-organ production facilities in Minnesota and Texas. United Therapeutics also detailed a $2.0 billion share repurchase program, including approximately $1.5 billion of accelerated share repurchases totaling 2,759,343 shares, and reported $3,803.4 million in cash, cash equivalents, and marketable investments as of June 30, 2026.
United Therapeutics Corporation reported six‑month 2026 revenue of $1,564.8 million, down from $1,593.0 million in 2025, while net income was $607.9 million versus $631.7 million. Operating income fell to $656.6 million from $747.3 million as cost of sales and research and development increased.
Cost of sales rose to $232.9 million, including $64.1 million of inventory reserves, largely tied to Tyvaso DPI supply commitments. Other income declined to $34.4 million from $84.6 million, driven by $48.2 million of net unrealized losses on equity securities, partly offset by a $12.8 million upward revaluation of a private investment. The effective tax rate dropped to 12 percent from 24 percent, reflecting higher excess tax benefits from share‑based compensation and the One Big Beautiful Bill Act.
Cash generation remained strong, with $776.9 million provided by operating activities. The company executed an accelerated share repurchase, paying $1,500.0 million and retiring 2,759,343 shares under 2026 agreements, leaving $500 million authorized for additional repurchases. Cash and cash equivalents increased to $1,803.2 million, while available‑for‑sale debt securities declined to $1,921.5 million as funds moved into cash and time deposits. Total assets were $7,220.1 million and stockholders’ equity $6,400.3 million as of June 30, 2026. The company also disclosed a July 2026 agreement to acquire Thymmune Therapeutics for $140.0 million upfront plus up to $160.0 million in milestones, expected to be expensed as in‑process R&D in the third quarter.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, through family trusts exercised 9,500 stock options at $135.42 and sold 9,500 shares of common stock on August 3, 2026 at weighted-average prices between $514.83 and $518.61, under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust held 217,910 options expiring March 15, 2027, while Rothblatt held 40,513 shares directly and 166 shares indirectly via a spouse.
United Therapeutics (UTHR) insider Martine Rothblatt, through Morgan Stanley Smith Barney LLC Executive Financial Services, filed to sell 199,500 shares of common stock under Form 144. The proposed sale, related to an exercise of stock options on 08/03/2026, reflects an aggregate market value of $103,283,145.00, with prior sales over the past three months made under a Rule 10b5-1 trading plan.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share on July 31, 2026, acquiring 9,500 common shares. The trusts then sold 9,500 shares that day in multiple reported transactions at weighted-average prices, all under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust continued to hold 227,410 options, while Rothblatt also held 40,513 shares directly and 166 shares indirectly through her spouse, plus additional holdings in family trusts.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts where she shares investment power, exercised 9,500 stock options at a strike price of $135.42 to acquire the same number of common shares, then sold 9,500 shares in several open-market or private transactions at weighted average prices in the low $520s per share. The option exercise and related sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026.